Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Basil S Lewis

Showing results (201-210 of 240) with videos related to

Pageof 24
Sort By:
European Heart Journal|March 21, 2025
2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and preventionPeter Jüni, Sotiris Antoniou, Elena Arbelo, et al.
European Journal of Heart Failure|December 3, 2020
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 31, 2021
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyEmma F Magavern, Juan Carlos Kaski, Richard M Turner, et al.
Stroke|May 14, 2021
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 TrialJackie Bosch, Eva M Lonn, Gilles R Dagenais, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 27, 2021
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyEmma Forton Magavern, Juan Carlos Kaski, Richard M Turner, et al.
Circulation|April 1, 2020
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS TrialDeepak L Bhatt, John W Eikelboom, Stuart J Connolly, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 9, 2019
Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular DiseasesGianluigi Savarese, Martin F Reiner, Alicia Uijl, et al.
Revista Espanola De Cardiologia (English Ed.)|May 22, 2021
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationJean-Philippe Collet, Holger Thiele, Emanuele Barbato, et al.
Circulation|March 18, 2020
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)Kevin R Bainey, Robert C Welsh, Stuart J Connolly, et al.
European Heart Journal|August 30, 2020
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationJean-Philippe Collet, Holger Thiele, Emanuele Barbato, et al.
Pageof 24

Showing results (201-210 of 240) with videos related to

Sort By:
Pageof 24
European Heart Journal|March 21, 2025
2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and preventionPeter Jüni, Sotiris Antoniou, Elena Arbelo, et al.
European Journal of Heart Failure|December 3, 2020
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 31, 2021
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyEmma F Magavern, Juan Carlos Kaski, Richard M Turner, et al.
Stroke|May 14, 2021
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 TrialJackie Bosch, Eva M Lonn, Gilles R Dagenais, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 27, 2021
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyEmma Forton Magavern, Juan Carlos Kaski, Richard M Turner, et al.
Circulation|April 1, 2020
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS TrialDeepak L Bhatt, John W Eikelboom, Stuart J Connolly, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 9, 2019
Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular DiseasesGianluigi Savarese, Martin F Reiner, Alicia Uijl, et al.
Revista Espanola De Cardiologia (English Ed.)|May 22, 2021
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationJean-Philippe Collet, Holger Thiele, Emanuele Barbato, et al.
Circulation|March 18, 2020
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)Kevin R Bainey, Robert C Welsh, Stuart J Connolly, et al.
European Heart Journal|August 30, 2020
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationJean-Philippe Collet, Holger Thiele, Emanuele Barbato, et al.
Pageof 24